Immune therapy institute launched
Print Edition
Shanghai has accelerated its pace of immunological research to take the lead in boosting China’s innovation in the prevention and treatment of immunological diseases.
The newly launched Shanghai Immune Therapy Institute is the latest example of the city’s efforts to build world-class immunology research hubs.
Established at Renji Hospital under Shanghai Jiao Tong University School of Medicine, the institute will focus on three research areas: tumor immunotherapy, chronic inflammatory diseases and transplantation immunology, and infectious diseases and vaccines.
It aims to become a frontier research and development center with global talent by 2025, and one of the world’s leading institutes in the fields of new drug targets, new mechanisms, antibody-drug development, immunotherapy and other major immune-related diseases by 2035, according to a hospital statement.
Jointly developed by the municipal government and the university, the institute is also expected to be a core element of Shanghai’s world-class biomedical industry cluster.
Immunology is highly relevant to the prevention and treatment of major diseases such as tumors, infectious diseases and metabolic diseases.
“Each breakthrough in immunology can lead to leap-forward development in medicine and the biomedical industry,” said Fan Xianqun, head of the university’s School of Medicine, at the launch of the institute last week.
Fan noted the institute’s researchers would look to make groundbreaking discoveries to promote China’s innovation and competitiveness in immunological disease prevention and control.
Dong Chen, director of the institute and an academician with the Chinese Academy of Sciences, said that China has made progress in the immunological field in recent years, but there is still a gap between basic research and clinical practice.
“The institute will help solve the problem,” said Dong, adding that establishing a research institute at a hospital can help in the process of taking a research concept from “the (laboratory) bench to the bedside.”
The institute will allow researchers to work closely with clinicians, bringing research advances from the lab into the clinic and taking clinical observation back to the bench for evaluation, which will benefit patients, Dong explained.
The director also stressed the importance of talent cultivation and said the main force of the institute will be young scientists under the age of 35.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
